The biotech industry is working tirelessly to identify new advancements to diagnose, treat, and prevent COVID-19 and help save lives around the world. For a recent I AM BIO podcast, BIO CEO Jim Greenwood sat down with Dr. Julie Gerberding, Executive Vice President at Merck and former head of the…

We are living in unprecedented times, as cases of coronavirus (COVID-19) rapidly increase while the world struggles to contain the pandemic. The biotechnology industry has stepped up to help combat this public health threat, working tirelessly to develop potential treatments, diagnostics and…

As the novel coronavirus continues to spread, scientists and researchers are working around the clock to identify diagnostics, therapeutics and vaccines to help protect individuals and communities across the globe. This week, leaders within the biopharmaceutical industry took to the airwaves,…

“We will continue doing what we do best -- find new therapeutics to solve this crisis. Let’s all focus on this mission and not politics.” – Dr. Jeremy Levin, Biocentury Scientists and researchers at America’s biopharmaceutical companies are working around the clock to develop vaccines,…

The Personalized Medicine Coalition has released its annual report on precision medicine trends at the Food and Drug Administration (FDA). Their analysis covers FDA approvals in 2019, including new milestones in the continued pursuit of the precision medicine paradigm—the right drug for the patient…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

We’re seeing an “extraordinary level” of biotech innovation, said BIO Chair Jeremy Levin, CEO of Ovid Therapeutics Inc., while kicking off the 22nd BIO CEO & Investor Conference on February 10th in New York. Day #1 of the conference featured discussions about the breakthrough therapies of the…

“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

As the biotech industry advances scientific discovery around new tumor types and mechanisms of action, we’ve seen more than 2,000 combination trials launched to enhance PD-1/L1 checkpoint inhibitors’ effects on solid tumors. The oncology pipeline has some exciting new biotechnological approaches…

At the time this blog was published, the coronavirus had taken more than 500 lives across the globe and infected more than 28,000 people across 25 countries. While these numbers are alarming, hope is on the horizon – and America’s biopharmaceutical industry is leading the charge.  In a…